Revenue Expectations - The company expects to achieve an annual revenue of approximately 1,949 million yuan in 2024, representing a year-on-year increase of about 29.71% compared to 2023[2]. - The increase in revenue is primarily driven by the sales of commercialized drugs, with significant growth in the sales of the core product, Toripalimab, in the domestic market[5]. R&D Expenses - The estimated R&D expenses for 2024 are approximately 1,274 million yuan, a decrease of about 34.24% compared to the previous year[2]. - The company is focusing on cost control and enhancing sales efficiency, which has contributed to the reduction in R&D expenses while maintaining progress in core pipeline projects[6]. Profit Projections - The net profit attributable to the parent company is expected to be around -1,292 million yuan for 2024, reflecting a reduction in losses by approximately 43.42% year-on-year[2]. - The net profit attributable to the parent company after deducting non-recurring gains and losses is projected to be around -1,273 million yuan, with a year-on-year loss reduction of about 44.59%[2]. Product Development and Approvals - New indications for Toripalimab have received approval from the National Medical Products Administration, including applications for advanced triple-negative breast cancer and advanced renal cell carcinoma[6]. - The company is accelerating the development and application for later-stage pipeline products, including anti-tumor antibodies and other innovative therapies[7]. Global Expansion - The company has expanded its global commercialization network, with Toripalimab approved for sale in multiple countries including the USA, EU, and Australia[5]. Forecast Accuracy - There are no significant uncertainties affecting the accuracy of this earnings forecast[8].
君实生物(688180) - 2024 Q4 - 年度业绩预告